Cite
HARVARD Citation
Pemov, A. et al. (2019). Low mutation burden and frequent loss of CDKN2A/B and SMARCA2, but not PRC2, define premalignant neurofibromatosis type 1–associated atypical neurofibromas. Neuro-oncology. 21 (8), pp. 981-992. [Online].